Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) Research & Development (2019 - 2022)

Nutex Health (NUTX) has disclosed Research & Development for 4 consecutive years, with $73750.0 as the latest value for Q1 2022.

  • For Q1 2022, Research & Development fell 3.87% year-over-year to $73750.0; the TTM value through Mar 2022 reached $282910.0, down 45.5%, while the annual FY2021 figure was $285880.0, 48.7% down from the prior year.
  • Research & Development hit $73750.0 in Q1 2022 for Nutex Health, down from $77265.0 in the prior quarter.
  • Across five years, Research & Development topped out at $314255.0 in Q2 2020 and bottomed at $54296.0 in Q4 2020.
  • Average Research & Development over 4 years is $129614.6, with a median of $77265.0 recorded in 2021.
  • On a YoY basis, Research & Development climbed as much as 42.3% in 2021 and fell as far as 81.03% in 2021.
  • Nutex Health's Research & Development stood at $196632.0 in 2019, then tumbled by 72.39% to $54296.0 in 2020, then soared by 42.3% to $77265.0 in 2021, then decreased by 4.55% to $73750.0 in 2022.
  • According to Business Quant data, Research & Development over the past three periods came in at $73750.0, $77265.0, and $72266.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.